 |
|
T-Cell Interferon Gamma Receptor Binding in Interferon Beta-1b–Treated Patients With Multiple Sclerosis
Paolo Bongioanni, MD, PhD;
Francesco Lombardo, MD;
Gianluca Moscato, MD;
Serena Mosti, MD;
Giuseppe Meucci, MD
Arch Neurol. 1999;56:217-222.
ABSTRACT
| |
Objective To investigate the effects of interferon beta treatment on T-cell interferon gamma binding (which is a possible marker for T-cell–dependent immune function) in patients with multiple sclerosis (MS).
Design Assay interferon gamma binding on T lymphocytes from patients with stable relapsing-remitting MS before, 3 months after, and 6 months after initiating interferon beta-1b treatment.
Setting The study was performed on ambulatory patients in a tertiary care center, where patients were diagnosed as having definite MS.
Patients Eighteen patients with clinically definite, stable, relapsing-remitting MS (13 women and 5 men; mean age [± SD] 32.6 ± 7.1 years) were selected consecutively. Clinical status was defined according to the Kurtzke Expanded Disability Status Scale. All patients were treated with 8 x 106 IU interferon beta-1b subcutaneously every other day. Eighteen age- and sex-matched healthy subjects with no family history of neuropsychiatric disorders formed the control group.
Results T lymphocytes from untreated patients with MS had significantly smaller amounts of interferon gamma receptors than those from control subjects (638 ± 7 [SE] vs 707 ± 11 [SE] receptors per cell). After 3 months of interferon beta-1b treatment, they showed a significant increase in interferon gamma binding (681 ± 9 [SE] receptors per cell). After 6 months, T-cell interferon gamma maximal receptor values were even higher (700 ± 7 [SE] receptors per cell), only slightly lower than those of control subjects.
Conclusion Given that reduced interferon gamma binding might be related to lymphocyte activation, our data seem to demonstrate that the major effect of interferon beta-1b treatment is a decrease in T-cell activation.
INTRODUCTION
MULTIPLE sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). Current opinion holds that immune-mediated factors are likely to be involved in MS pathogenesis.1-2 Cytokines represent important modulators of cell-to-cell interactions, even in the CNS3-4; the unbalanced immune response in patients with MS might depend on derangement of a cytokine network. Among cytokines, interferons play an important role; they are classically defined as having antiviral activity. In addition, they are known to be potent antiproliferative and immunomodulatory agents. Two interferon types have been identified: type I, including interferon alfa and interferon beta, produced during viral or bacterial infection; and type II, interferon gamma, which is produced primarily by T lymphocytes on mitogen or antigen stimulation. The immune effects of interferon gamma include promoting T- and B-cell proliferation, generating cytotoxic T-lymphocyte activity, inducing high-affinity interleukin (IL) 2 receptor (IL-2R) expression, modulating antibody, IL-1, and tumor necrosis factor production, and increasing expression of major histocompatibility complex (MHC) molecules on the surface of many cell types.5
In the CNS of patients with MS, interferon gamma is closely associated with active plaques on glial elements. Interferon gamma is able to induce expression of MHC class II molecules on gliocytes6; antigen presentation by MHC positive astrocytes could enhance the local immune response, thus facilitating continuous growth of lesions. Significantly higher cerebrospinal fluid interferon gamma levels have been found in patients with MS than in subjects with other neurological diseases,7 although some discordant results have been reported.8
Interferon gamma treatment worsens MS symptoms9 and seems to provoke MS attacks; before the attacks, enhanced serum interferon gamma concentrations have been found.10 Higher numbers of interferon gamma messenger RNA–expressing cells in response to myelin basic protein and proteolipid protein have been detected in the cerebrospinal fluid and serum of untreated patients with MS than in subjects with other neurological diseases.11
Studies of parenterally administered human recombinant type I interferons in patients with relapsing-remitting (RR) MS reported fewer relapses,12-13 a reduction of progression,14 and a significant reduction in average number of gadolinium-enhancing lesions detected on magnetic resonance imaging scans in treated patients.14-15 Brod et al16 found that in patients with stable RR MS treated with interferon beta-1b, on-treatment peripheral blood mononuclear cells stimulated with concanavalin A secreted significantly more interferon gamma, tumor necrosis factor  , IL-2, IL-6, IL-10, and less IL-4 than concanavalin A–stimulated pretreatment mononuclear cells.
Interferon gamma exerts its effects through binding to specific receptors, ie, transmembrane glycoproteins of 472 amino acids with an apparent molecular mass of 90 kd, biochemically distinct from the receptors for type I interferons.17-18 Interferon gamma receptors belong to a single class of high-affinity receptors with a dissociation constant in the picomolar to nanomolar range, expressed in various human tissues, including peripheral blood mononuclear cells.19-21 Freshly isolated normal human T cells activated in vitro with phytohemagglutinin, concanavalin A, or phorbol myristate acetate have been reported to express fewer interferon gamma receptors than resting lymphocytes.22 A functional interferon gamma receptor requires at least 2 components: one is a ligand-binding molecule, and the other is a signal-transducing, species-specific factor encoded by a gene on chromosome 21.23-24 A membrane proximal region is required for ligand processing and Janus kinase binding.25 The binding of interferon gamma to its receptor, through the Janus kinase activation, induces phosphorylation of Stat1 (a member of a family of transcription factors) causing its dimerization and moving to the nucleus, where Stat1 binds the gamma-activated sequence in interferon gamma–responsive genes.25
We measured interferon gamma receptor binding on T cells from untreated patients with MS,26 finding significantly lower numbers of interferon gamma receptors on lymphocytes from patients than on those from age-matched healthy control subjects: the lowest values were observed in patients with RR MS during relapses (407 ± 25 [SE] receptors per cell).
The aim of the present work has been to assay peripheral blood T-cell interferon gamma binding in interferon beta-1b–treated patients with RR MS as compared with healthy control subjects, and to study the in vivo effects of interferon beta-1b on T-cell activation, which seems to be linked to a down-regulation of interferon gamma receptors.
SUBJECTS, MATERIALS, AND METHODS
SUBJECTS
Eighteen patients with clinically definite, stable RR MS27 were consecutively selected at the Department of Neurosciences, Section of Neurology, University of Pisa in Italy. The RR course was defined as the occurrence of clear episodes of disease worsening over 24 to 48 hours with full or partial recovery.28 Clinical status was defined according to the Kurtzke Expanded Disability Status Scale.29 There were 5 men and 13 women, aged 24 to 46 years (mean ± SD age, 32.6 ± 7.1 years). Disease onset ages ranged from 16 to 41 years; disease duration, 1 to 11 years; and Kurtzke9 Expanded Disability Status Scale scores, 1 to 3.5 (Table 1).
|
|
|
|
Clinical Features of Patients
|
|
|
T-cell interferon gamma binding was measured in all patients before the initiation of alternate-day subcutaneous treatment with 8 x 106 IU interferon beta-1b30 and after 3 months and 6 months during therapy (on-treatment). Serum IL-2 and soluble IL-2R levels were used as markers for circulating activated T cells31: for IL-2 and soluble IL-2R immunoenzymatic assays, commercial kits (Genzyme Srl, Milan, Italy) were used. Patients were monitored for adverse effects during the 6-month period, including systemic symptoms, local injection site reaction, and changes in peripheral total leukocyte count and lymphocyte count.
At the time of the first observation and blood sampling, none of the patients had received corticosteroids for at least 1 month, or immunosuppressive drugs for at least 6 months; during interferon beta-1b treatment none of them received immunosuppressive medications. No subject showed any symptoms or signs of concurrent infection either before or during interferon beta-1b therapy.
The control population consisted of 18 age- and sex-matched healthy subjects selected among blood donors or laboratory personnel, aged 18 to 51 years (mean age ± SD, 31.7 ± 9.6 years).
METHODS
Separation of T Cells From Peripheral Blood
Venipuncture was performed on all subjects after informed consent between 7 AM and 8 AM to avoid circadian variations of lymphocyte subsets.32 Blood was centrifuged with Ficoll-Paque (Amersham Pharmacia Biotech Italia, Milan, Italy) at 400g for 30 minutes at room temperature. Buffy coats of mononuclear cells were spun at 800g for 10 minutes at 4°C to get cell pellets. After cell counting with a Neubauer hemocytometer, mononuclear cells in Dulbecco modified minimal Eagle medium (Sigma Aldrich Srl, Milan) with 10% fetal calf serum (Bio-Whittaker International PBI Spa, Milan) were plated overnight in Petri dishes at 4°C to separate peripheral blood lymphocytes from macrophages. Peripheral blood lymphocytes were incubated in Dulbecco modified minimal Eagle medium with 10% fetal calf serum at 4°C for 2 hours in mouse anti–human IgG (Sigma)–coated Petri dishes. Such a panning procedure was repeated 3 times so that we got 97% pure T-cell suspensions. T lymphocytes were identified morphologically and as Leu4+ cells by flow cytometry (Figure 1). No significant differences were observed among various subject groups.
|
|
|
|
Figure 1. Cell suspensions of 100 µL (either from freshly isolated mononuclear cells or from purified lymphocyte cell cultures [see "Subjects, Materials, and Methods" section]), were incubated in the dark for 20 minutes with 5 µL of fluorescein-isothiocyanate–conjugated monoclonal antibodies against CD3 (a marker for total T cells) (anti-Leu4; Becton Dickinson Italia Spa, Milan, Italy). Samples were counted through a flow cytometer (Epics XL-MCL; Coulter Electronics Ltd, Luton, England) equipped with a single 15-mW argon ion laser (excitation wavelength of 488 nm in combination with a 530-nm bandpass filter). Fluorescein-isothiocyanate–conjugated mouse IgG was used to evaluate nonspecific fluorescence. To exclude monocytes, other leukocytes, and debris, gates were selected on lymphoid cells, as determined by forward and right-angle scatter. Overlaid histograms of CD3+ cells in freshly isolated (1) and purified (2) cell cultures from a patient with multiple sclerosis (top) and a control subject (bottom).
|
|
|
T-Cell Interferon Gamma Binding
We radioactively labeled recombinant human (RH) interferon gamma with iodine 125 (Genzyme) (specific antiviral activity: 1 x 107 U/mg of protein) according to the method previously described.26 In standard binding assays, 6 x 106 T cells from each subject were incubated in duplicate at 4°C in 750 µL Dulbecco modified minimal Eagle medium with HEPES buffer (10 mmol/L, pH 7.4) and 10% fetal calf serum for 2 hours with different amounts of 125I–RH interferon gamma (0.1-0.5 ng). In competitive binding experiments, increasing amounts of unlabeled RH interferon gamma were added to standard binding assays. Nonspecific binding was determined by adding in duplicate a 100-fold excess of unlabeled RH interferon gamma. Radioactivity was counted in a gamma counter (Beckman Italia Spa, Milan) with 50% efficiency. Final results about binding parameters were achieved through the Scatchard equation, using McPherson's33 Ligand program (version 3.1, 1985), which determines the maximal receptor number (Bmax) and the dissociation constant (Kd). A molecular weight of 34 kd, corresponding to the dimeric form of RH interferon gamma, was used for calculations. Statistical evaluation was performed using the 2-tailed Student t test and analysis of variance, according to the number ( 2) of subject groups to be compared.
RESULTS
We found that T cells from patients with MS and healthy control subjects constitutively express high-affinity interferon gamma receptors. The binding of 125I–RH interferon gamma was specific: only unlabeled RH interferon gamma significantly inhibited the binding, while the same amounts (100 ng) of RH interferon alfa or RH interferon beta were ineffective. A representative experiment set of competitive binding of 125I–RH interferon gamma and unlabeled RH interferon gamma to T cells is shown in Figure 2. Enriched T-cell suspensions were incubated with 125I–RH interferon gamma (0.5 ng) and different amounts of unlabeled RH interferon gamma. Scatchard analysis of the data yielded a linear plot (Figure 3) suggesting a single binding site model. Saturation binding experiments resulted in similar findings.
|
|
|
|
Figure 2. Highly enriched T cells have been incubated with 0.5 ng radioactively labeled iodine 125 recombinant human interferon gamma and the above-indicated amounts of unlabeled recombinant human interferon gamma. The binding of 125I–recombinant human interferon gamma is expressed as a percentage of the binding in the absence of unlabeled radioiodinated human interferon gamma.
|
|
|
|
|
|
|
Figure 3. Scatchard analysis of iodine 125 radioactively labeled recombinant human interferon gamma binding to T cells.
|
|
|
Differences in Kd values were not found between patients with MS and healthy control subjects (1.1 ± 0.06 [SE] vs 1.0 ± 0.04 [SE] nmol/L), or among pretreatment and on-treatment groups. On the contrary, highly significant (P<.001) differences in Bmax values were observed between untreated patients and control subjects (Figure 4): 638 ± 7 (SE) vs 707 ± 11 (SE) receptors per cell. Interferon beta-1b therapy was associated with an increase in T-cell interferon gamma receptor number: Bmax values were significantly (P<.001) higher 3 months after initiation of treatment (681 ± 9 [SE] receptors per cell). At 6 months, Bmax values increased further (700 ± 7 [SE] receptors per cell), although not significantly compared with 3-month values. There was a statistically significant (P<.005) difference in T-cell interferon gamma receptor Bmax values between patients with MS 3 months after initiation of interferon beta-1b therapy and control subjects, whereas patients' 6-month values did not differ from those of control subjects. Linear regression analysis performed on groups of patients with MS resulted in no significant correlations between serum IL-2 levels and interferon gamma receptor Bmax values, or between soluble IL-2R levels and 125I–RH interferon gamma binding (data not shown).
|
|
|
|
Figure 4. The maximal receptor values of radioactively labeled iodine 125 recombinant human interferon gamma binding on T cells from patients with multiple sclerosis (before, 3 months after, and 6 months after initiating treatment with interferon beta-1b) and age-matched healthy control subjects. Three asterisks indicates P<.001; 2 asterisks, P<.005 (patients with multiple sclerosis vs controls).
|
|
|
In separate in vitro experiments with T lymphocytes from healthy control subjects (Figure 5), we observed a significantly increased (P<.001) expression of high-affinity interferon gamma receptors (Kd: 0.9 ± 0.06 [SE] nmol/L) on concanavalin A–stimulated T cells treated with interferon beta-1b (500 U/mL), as compared with untreated control T lymphocytes activated with concanavalin A (5 ng/mL) (698 ± 16 vs 311 ± 15 [SE] receptors per cell). Interferon gamma Bmax values of interferon beta-1b–treated T cells resembled those of freshly isolated unstimulated T lymphocytes from healthy control donors (708 ± 13 [SE] receptors per cell).
|
|
|
|
Figure 5. Interferon gamma binding assay in interferon beta-1b–treated and untreated concanavalin A–activated T lymphocytes from healthy control donors. P value was <.001 (interferon beta–treated vs untreated T cells).
|
|
|
COMMENT
Multiple sclerosis is an inflammatory disease involving the white matter of the CNS. Although there is a localized immune response within the CNS, disease-related immune changes are also found in peripheral blood lymphocytes.26, 34-36 Interferon gamma is a cytokine with pleiotropic effects; in particular, it is able to modulate the immune network both in the CNS and systemically. The initial event in the action of interferon gamma is the binding to specific receptors found on different cell types, including peripheral blood lymphocytes.22, 26, 37-38 The binding of interferon gamma to its receptor plays an obligate role in T-lymphocyte activation.22, 26
In the present work, we have found that untreated patients with MS have a significantly reduced number of T-cell interferon gamma receptors compared with healthy control subjects, thus confirming our previous findings.26 Since activated lymphocytes have fewer interferon gamma receptors than resting ones have,22, 26 these data give further support for the presence of a systemic T-cell activation in MS.
In the present work, we did not find significant correlations between serum IL-2 levels and interferon gamma receptor Bmax values (P = .09) or between soluble IL-2R levels and 125I–RH interferon gamma binding (P = .07). On the contrary, many research groups have reported an association between IL-2R expression (and/or IL-2 production) and T-cell activation in MS.31 In our previous research work,26 we too found a significant (P<.01) negative correlation between serum IL-2 levels and T-cell interferon gamma binding in patients with relapsing and evolutive MS (but not in stable patients); moreover, by reexamining in a stable phase 6 patients with MS with relapses showing a significant (P<.05) negative correlation between serum IL-2 and interferon gamma receptor values, we did not observe any such significant correlation in the stable phase (P = .2). Therefore, the lack of a significant correlation between serum IL-2 levels and lymphocyte interferon gamma binding might depend on the fact that in the present work we studied patients with clinically definite, stable RR MS.
Interferon beta-1b is associated with an increase in the interferon gamma receptor number on T cells from patients with MS 3 months and even 6 months after the initiation of treatment. Interferon beta is an immunomodulatory cytokine, and its beneficial effect in MS might depend on its ability to regulate the 3 phases of immune response:it might lessen activation, blunt assault, or increase deactivation, or it might cause some combination of these 3. Interferon beta counteracts the protean immune-augmenting effects of interferon gamma, in particular interferon gamma–enhanced MHC expression on the surface of macrophages and astrocytes acting as antigen-presenting cells39-40; an agent such as interferon beta, which lessens the capacity for antigen presentation to T cells, is expected to attenuate T-cell responses. Moreover, interferon beta reduces the release of interferon gamma and tumor necrosis factor from cultured mononuclear cells41-43 and promptly restores the deficient suppressor function in patients with MS, at least in vitro.44
An interferon beta-1b treatment–dependent increase in the number of T-cell interferon gamma receptors might be due, at least in part, to the antagonistic action of interferon beta-1b on interferon gamma, which is able to down-regulate its own receptors, as shown by the effects of anti–interferon gamma monoclonal antibodies in preventing a large portion of the phytohemagglutinin-induced decrease of interferon gamma Bmax values.22 Given that less activated lymphocytes seem to have increased interferon gamma binding,26 the interferon beta-1b up-regulating effect on T-cell interferon gamma receptors might represent a favorable immunomodulatory mechanism: the T-cell–activated state (as marked by decreased interferon gamma binding) is progressively reduced during treatment (as shown by increased T-cell interferon gamma receptor numbers approaching more and more those of control subjects).
AUTHOR INFORMATION
Accepted for publication May 26, 1998.
Reprints: Paolo Bongioanni, MD, PhD, Department of Neurosciences, Section of Neurology, University of Pisa, Via Roma 67, 56126 Pisa, Italy (e-mail: Bongioanni{at}sssup1.sssup.it).
From the University of Pisa, Department of Neurosciences, Section of Neurology, Pisa, Italy.
REFERENCES
| |
1. O'Gorman M, Oger J. Cell-mediated immune functions in multiple sclerosis. Pathol Immunopathol Res. 1987;6:241-272.
ISI
| PUBMED
2. Raine CS. The Dale E. McFarlin memorial lecture: the immunology of the multiple sclerosis lesion. Ann Neurol. 1994;36:S61-S72.
3. Nicola NA. Guidebook to Cytokines and Their Receptors. Oxford, England: Sambrook & Tooze Publication at Oxford University Press; 1994.
4. Ransohoff RM, Benveniste EN. Cytokines and the CNS. London, England: CRC Press Inc; 1996.
5. Trinchieri G, Perussia B. Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today. 1985;6:131-136.
6. Bongioanni P. Immuno-interferon effect on cultured rat astrocytes [abstract]. J Neurol. 1990;237:S49.
7. Perrella O, Carrieri PB, De Mercato R, Buscaino GA. Markers of activated T lymphocytes and T cell receptor gamma/delta+ in patients with multiple sclerosis. Eur Neurol. 1993;33:152-155.
ISI
| PUBMED
8. Gallo P, Piccinno MG, Pagni S, et al. Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and IFN- levels in serum and CSF. J Neurol Sci. 1989;92:9-15.
FULL TEXT
|
ISI
| PUBMED
9. Panitch HS, Haley AS, Hirsch RL, Johnson KP. Exacerbations of MS in patients treated with gamma-IFN. Lancet. 1987;1:893-895.
ISI
| PUBMED
10. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon- and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Ann Neurol Scand. 1988;78:318-323.
11. Link J, Soderstrom M, Olsson T, Hojeberg B, Ljungdahl A, Link H. Increased TGF- , IL-4, and IFN- in multiple sclerosis. Ann Neurol. 1994;36:379-386.
FULL TEXT
|
ISI
| PUBMED
12. IFNB MS Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology. 1993;43:655-661.
FREE FULL TEXT
13. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology. 1994;44:406-413.
ISI
14. Jacobs L, Cookfair D, Rudick R, et al and the MS Collaborative Group. Results of a phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis. Ann Neurol. 1994;36:259.
FULL TEXT
15. IFNB MS Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, II: MRI analysis results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology. 1993;43:662-667.
FREE FULL TEXT
16. Brod SA, Marshall GD Jr, Henninger EM, Sriram S, Khan M, Wolinsky JS. Interferon-1b treatment decreases tumor necrosis factor- and increases interleukin-6 production in multiple sclerosis. Neurology. 1996;46:1633-1638.
FREE FULL TEXT
17. Novick D, Orchansky P, Revel M, Rubinstein M. The human interferon- receptor. Purification, characterization and preparation of antibodies. J Biol Chem. 1987;262:8483-8487.
FREE FULL TEXT
18. Fischer T, Thoma B, Scheurich P, Pfizenmaier K. Glycosylation of the human interferon- receptor: N-linked carbohydrates contribute to structural heterogeneity and are required for ligand binding. J Biol Chem. 1991;265:1710-1717.
FREE FULL TEXT
19. Littman SJ, Faltynek CR, Baglioni C. Binding of human recombinant 125I–interferon- to receptors on human cells. J Biol Chem. 1985;260:1191-1198.
FREE FULL TEXT
20. Sarkar FH, Gupta SL. Receptors for human -interferon: binding and cross-linking of 125I-labeled recombinant human -interferon to receptors on WISH cells. Proc Natl Acad Sci U S A. 1984;81:5160-5167.
FREE FULL TEXT
21. Valente G, Ozmen L, Novelli F, et al. Distribution of interferon- receptor in human tissues. Eur J Immunol. 1992;22:2403-2412.
ISI
| PUBMED
22. Faltynek CR, Princler GL. Modulation of interferon- and interferon- receptor expression during T-lymphocyte activation and proliferation. J Interferon Res. 1986;6:639-653.
ISI
| PUBMED
23. Gibbs VC, Williams SR, Gray PW, et al. The extracellular domain of the human interferon gamma receptor interacts with a species-specific signal transducer. Mol Cell Biol. 1991;11:5860-5866.
FREE FULL TEXT
24. Fountoulakis M, Lahm HW, Maris A, et al. A 25-kD stretch of the extracellular domain of the human interferon receptor is required for full ligand binding capacity. J Biol Chem. 1991;266:14970-14977.
FREE FULL TEXT
25. Ihle JN. Cytokine receptor signalling. Nature. 1995;377:591-594.
FULL TEXT
| PUBMED
26. Bongioanni P, Lombardo F, Fioretti C, Meucci G. T-lymphocyte immunointerferon receptors in patients with multiple sclerosis. J Neurol. 1996;243:605-610.
FULL TEXT
|
ISI
| PUBMED
27. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
FULL TEXT
|
ISI
| PUBMED
28. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907-911.
FREE FULL TEXT
29. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
FREE FULL TEXT
30. Quality Standards Committee, AAN. Practice advisory on selection of patients with multiple sclerosis for treatment with betaseron. Neurology. 1994;44:1537-1540.
FREE FULL TEXT
31. Trotter JL, Clifford DB, McInnis JE, et al. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol. 1989;25:172-178.
FULL TEXT
|
ISI
| PUBMED
32. Bertouch JV, Roberts-Thompson PJ, Bradley J. Diurnal variation of lymphocyte subsets identified by monoclonal antibodies. BMJ. 1983;286:1771-1772.
33. McPherson GA. Kinetic, EBDA, Ligand, Lowry. A Collection of Radioligand Binding Analysis Programs. Amsterdam, the Netherlands: Elsevier Science Publishers; 1985;31-102.
34. Noronha AB, Richman DP, Arnason BGW. Detection of in vivo stimulated cerebrospinal fluid lymphocytes by flow cytometry in patients with multiple sclerosis. N Engl J Med. 1980;303:713-717.
ABSTRACT
35. Hafler DA, Fox DA, Manning ME, et al. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med. 1985;312:1405-1411.
ABSTRACT
36. Bongioanni P, Fioretti C, Vanacore R, et al. Lymphocyte subsets in multiple sclerosis: a study with two-color fluorescence analysis. J Neurol Sci. 1996;139:71-77.
ISI
| PUBMED
37. Faltynek CR, McCandless S, Baglioni C. Single high affinity binding of interferon- to receptors on human lymphoblastoid cells: internalization and inactivation of receptors. J Cell Physiol. 1985;123:459-463.
FULL TEXT
|
ISI
| PUBMED
38. Faltynek CR, Princler GL, Ortaldo JR. Expression of IFN- and IFN- receptors on normal human small resting T lymphocytes and large granular lymphocytes. J Immunol. 1986;136:4134-4138.
ABSTRACT
39. Barna BP, Chou SM, Jacobs B, Yen-Lieberman B, Ransohoff RM. Interferon- impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J Neuroimmunol. 1989;23:45-53.
FULL TEXT
|
ISI
| PUBMED
40. Panitch HS, Folus JS, Johnson KP. Beta interferon prevents HLA class II antigen induction by gamma interferon in MS. Neurology. 1989;39(suppl 1):171.
41. Noronha A, Toscas A, Jensen MA. IFN-beta downregulates IFN-gamma production by activated T cells in MS [abstract]. Neurology. 1991;41(suppl 1):219.
42. Noronha A, Jensen MA, Toscas A, Sihag S. IFN-beta downregulates tumor necrosis factor release. Neurology. 1992;42(suppl 3):159-160.
43. Rudick RA, Carpenter CS, Cookfair DL, et al. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon-beta. Neurology. 1993;43:2080-2087.
FREE FULL TEXT
44. Noronha A, Toscas A, Jensen MA. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol. 1990;27:207-210.
FULL TEXT
|
ISI
| PUBMED
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(2):254-255.
FULL TEXT
|
